Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous infusion use. It is indicated for metastatic colorectal cancer and other solid tumours in adult patients, and is classified under ATC code L01XX02.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network adheres to stringent quality standards and regulatory requirements across EU and global markets, ensuring reliable supply and patient safety.

Irinotecan is a topoisomerase I inhibitor used in the treatment of solid tumours.

- Metastatic colorectal cancer: improves survival and disease control in adult patients. - Advanced gastric cancer: used in combination regimens to achieve tumour response. - Pancreatic cancer: part of combination therapy to target tumour growth. - Other solid tumours: provides therapeutic benefit as part of multi‑agent protocols.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: frequent loose stools that may lead to dehydration. - Nausea: feeling of sickness often accompanied by vomiting. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: intense inflammation of the colon causing abdominal pain. - Hepatic toxicity: elevated liver enzymes indicating liver injury. - Allergic reactions: rash, itching, or anaphylaxis needing immediate treatment.

When using Irinotecan, several precautions should be observed to minimize risks.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Hydration: maintain adequate fluid intake to reduce risk of severe diarrhea. - Pregnancy: contraindicated; avoid use in pregnant women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce SN‑38 exposure and decrease effectiveness. - UGT1A1 inhibitors: increase SN‑38 levels and risk of toxicity. - Concurrent myelosuppressive agents: heightened risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect metabolism and require dose adjustment. - Warfarin: monitor INR closely due to potential bleeding risk. - Fluoropyrimidines: increased gastrointestinal toxicity when combined.